More cohort studies concerning DNMT3A mutations are needed in an effort to further verify or modify the pooled estimates to a certain extent, especially for the patients with CN-AML or with cytogenetic intermediate risk abnormalities. Here, DNMT3A is linked to acute myeloid leukemia.